Yaohua Ma

Yaohua Ma

Auto-generated profile, based on publicly available information

Yaohua Ma

From the Mayo Clinic Florida, Jacksonville, Florida

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in JCO Precision Oncology
Verified
Journal Article
Closed access
MHMaeve A. Hennessy
Maeve A. Hennessy
ACAshley Cimino-Mathews
Ashley Cimino-Mathews
JCJodi M. Carter
Jodi M. Carter
JKJennifer M. Kachergus
Jennifer M. Kachergus
YMYaohua Ma
Yaohua Ma
RCRoisin M. Connolly
Roisin M. Connolly
PURPOSE: Predictive biomarkers to better tailor therapy for patients with early-stage human epidermal growth factor 2 (HER2)-positive breast cancer are a priority. We hypothesized that HER2 and immune-based biomarkers would be predictive of pathologic complete response (pCR) to preoperative trastuzumab/pertuzumab (HP). MATERIALS AND METHODS: Patients with stage II/III, estrogen receptor (ER)-negative, HER2-positive breast cancer received neoadjuvant HP in the TBCRC026 clinical trial. The pCR after receiving HP alone was 22% (18/83). Tumor biopsies were performed at baseline. Secondary correlative objectives were to determine the relationship between HER2-based biomarkers and immune processes with pCR. NanoString code sets BC360 and IO360 were used to compare differential gene expression in baseline tumors that underwent pCR versus no pCR. NanoString GeoMx digital spatial profiling was used to assess immune protein abundance in intraepithelial and stromal segments. Stromal tumor-infiltrating lymphocytes and Ki67 were evaluated by hematoxylin and eosin and immunohistochemistry, respectively. RESULTS: Intraepithelial HER2 protein abundance was significantly associated with pCR ( P = .001). Low HER2 abundance tumors were primarily basal-like, and essentially all (19/20) failed to achieve pCR. High HER2 abundance tumors that achieved pCR (14/51) exhibited a high degree of immune cell activity, whereas high HER2 abundance tumors that failed to achieve pCR tumors (37/51) were enriched for M-phase processes and epidermal growth factor receptor signaling. Baseline Ki67 was significantly higher in nonresponders ( P = .04). CONCLUSION: ER-negative, HER2-positive breast cancer has unique molecular and immunologic features that may predict pCR after neoadjuvant HP. Validation of these potential biomarkers and composite biomarker analyses may guide design of future clinical trials.


18 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
HAHumza M. Ashraf
Humza M. Ashraf
RMRaymond M. Moore
Raymond M. Moore
WSWilliam Sherman
William Sherman
YMYaohua Ma
Yaohua Ma
MEMattias Embretsen
Mattias Embretsen
JNJustin H. Nguyen
Justin H. Nguyen
The highest risk for liver allograft rejection is within the first weeks to months after a liver transplant; however, while later-stage mechanisms are well described, the initial window at the moment of alloantigen influx (e.g., ~1 h post-reperfusion) remains unmapped. T-cell priming is initiated in lymph nodes, yet these sites are rarely profiled in humans and their relationship to rejection risk is unclear. To address this gap, we profiled paired pre- and ~1 h post-reperfusion hepatic draining lymph nodes from liver transplant recipients using multiplexed immunofluorescence and GeoMx whole-transcriptome profiling to identify features that correlate with posttransplant allograft biopsy-proven rejection versus non-rejection. Early after reperfusion, CD4+ and CD8+ T cells became proximal to macrophages in rejection compared to dendritic cells in non-rejection, which also displayed an immunoregulatory-leaning profile marked by PD-1, IDO1, and CD39, suggesting that macrophages and dendritic cells differentially influence early T-cell alloimmunity. These results provide a “true-to-life” snapshot profile of initial dynamic immune cellular interactions of T cell alloimmunity within the hepatic lymph nodes in human liver transplantation.

10 September 2026 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
PDF file
LBLyle Wesley Baker
Lyle Wesley Baker
RKRohith Karthik
Rohith Karthik
VMVinay R. Munlapudi
Vinay R. Munlapudi
JBJonathan Balog
Jonathan Balog
MMMichael Mao
Michael Mao
IPIvan E. Porter
Ivan E. Porter
Office blood pressure (OBP) may be transiently elevated during clinical encounters because of situational anxiety and stress‐related physiologic arousal, contributing to diagnostic uncertainty and potential overtreatment. Virtual reality (VR)‐based relaxation can reduce stress‐related physiologic responses, but its effects on OBP and potential role in mitigating the white coat response among patients undergoing ambulatory blood pressure monitoring (ABPM) have not been evaluated. We conducted a prospective, single‐arm, pre‐post study among adults undergoing ABPM in a tertiary hypertension clinic. Participants completed paired OBP measurements and validated anxiety assessments before and after a brief immersive VR relaxation experience. ABPM results were used to classify predefined blood pressure subgroups. Seventy‐eight participants completed the study (mean age 62 ± 15 years; 47% female). Across the cohort, systolic OBP decreased by 6.1 mmHg (95% CI, −7.6 to −4.6; p < 0.001) and diastolic OBP by 1.4 mmHg ( p = 0.002) following VR exposure. Participants with a pronounced white coat response, prespecified as an office‐to‐daytime ambulatory systolic BP difference ≥15 mmHg, experienced the greatest systolic BP reduction (−12.2 mmHg; p < 0.001), compared with smaller or nonsignificant changes in other subgroups (between‐group p = 0.005). Following VR exposure, 32.1% of participants were reclassified to a lower OBP category. Anxiety scores decreased significantly, and no adverse effects were reported. A brief VR relaxation intervention was associated with significant reductions in OBP and anxiety, particularly among participants with a pronounced white coat response, supporting its potential as an adjunct for improving OBP assessment in hypertension clinics. Clinical Trial Registration: Clinical Trials. gov Identifier: NCT06960057